(Reuters) – CVS Caremark Corp said on Wednesday it was buying Coram LLC, Apria Healthcare Group Inc’s specialty infusion services and enteral nutrition business unit, for $2.1 billion.
CVS, which operates a drugstore chain and a pharmacy benefits management unit, said Coram would add $1.4 billion to revenues in the first year after the deal closes and 3 to 5 cents per share to CVS’s adjusted earnings per share in 2015. CVS expects the deal to close in the first quarter of 2014.
Infusion therapy involves administering medication through a needle or catheter when a patient’s condition is too severe to be treated effectively by oral medications.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.